Cover Image
市場調查報告書

全球腦瘤治療藥市場:成長,趨勢,預測

Global Brain Tumor Therapeutics Market - Segmented by Type of Cancer and Therapeutics - Growth, Trends and Forecasts (2018 - 2023)

出版商 Mordor Intelligence LLP 商品編碼 391488
出版日期 內容資訊 英文 111 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
全球腦瘤治療藥市場:成長,趨勢,預測 Global Brain Tumor Therapeutics Market - Segmented by Type of Cancer and Therapeutics - Growth, Trends and Forecasts (2018 - 2023)
出版日期: 2018年02月08日 內容資訊: 英文 111 Pages
簡介

本報告提供全球腦瘤治療藥市場相關調查,彙整市場趨勢與今後的成長預測,各類型,治療藥物別,各地區趨勢,及打入市場的主要企業簡介等資料。

第1章 簡介

第2章 調查方法

第3章 摘要整理

第4章 市場概要與產業趨勢

  • 目前市場方案
  • 波特五力分析

第5章 促進要素,阻礙要素,機會,課題分析

  • 推動市場的要素
  • 阻礙市場的要素
  • 市場機會
  • 課題

第6章 市場區隔

  • 各類型
    • 神經膠質瘤
    • 腦膜瘤
    • 下垂體腺瘤
    • 神經鞘腫
    • 髓母細胞瘤
  • 治療藥物別
    • 腦瘤

第7章 各地區市場區隔

  • 北美
  • 歐洲
  • 亞太地區
  • 中東·非洲
  • 南美

第8章 競爭環境

  • 開發平台(管線)有的藥物/產品上市
  • 合併·收購
  • 協定,聯合,聯盟

第9章 企業簡介

第10章 市場未來發展預測

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 1574

The global brain tumor therapeutics market has been estimated to reach USD 2.74 billion in 2023. The market is expected to register a CAGR of 11% during the forecast period 2018 to 2023. North America dominates the market due to the increasing technological advancements. Developed healthcare infrastructure, greater per capita healthcare spending, and comparatively higher awareness regarding advanced technologies are other impact rendering factors.

Increasing incidence of brain cancer and focus on precision medicine

Increasing incidence of Brain Cancer has resulted in upsurge the demand for brain cancer across the globe which is driving the market. In addition, increased focus on precision medicine is also fuelling the global brain tumor therapeutics market.

Few brain cancer specific drugs and high cost of treatment

Few brain cancer specific drugs and their high cost is acting as a restraint for Brain Tumor therapeutics market. Although various pharmaceutical companies are spending heavily on R&D activities which can bring more treatment options to the market in future.

North America to Dominate the Market

The Brain Tumor Therapeutics market is segmented by type of treatment and geography. By geography it is segmented into North America, Europe, Asia-Pacific, the Middle East and Africa and South America. North America dominates the Brain Tumor therapeutics market due to the increasing technological advancements and the rising incidence of brain cancer in the country. Asia-Pacific is also expected to propel the Brain Tumor therapeutics market owing to factors, such as increasing accessibility to healthcare facilities in the region, and increasing geriatric population.

Key developments in the market

In January, 2018 iTeos Therapeutics has regained rights to its Phase 1 brain cancer drug from Pfizer, and plans to continue oncology development.

In December, 2017, Diffusion Pharmaceuticals (DFFN) Launches Phase 3 Trial for Glioblastoma

Major key players: F. HOFFMAN LA-ROCHE LTD., MERCK, NOVARTIS, IMMUNOCELLULAR THERAPEUTICS, NOVOCURE, DELMAR PHARMACEUTICALS INC. MOLECULIN BIOTECH etc.

Reasons to purchase this report

Market analysis for the Global Brain Tumor Therapeutics Market, with region-specific assessments and competition analysis on a global and regional scale.

Analyzing various perspectives of the company with the help of Porter's five forces analysis

The treatment type that is expected to dominate the market

Regions that are expected to witness fastest growth during the forecast period

Identify the latest developments, market shares and strategies employed by the major market players.

3 months analyst support along with the Market Estimate sheet in excel.

Customization of the report

This report can be customized to meet your requirements. Please connect with our analyst, who will ensure you get a report that suits your needs.

Table of Contents

1. INTRODUCTION

  • 1.1 MARKET DEFINITION

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. KEY INFERENCES

5. MARKET OVERVIEW

  • 5.1 CURRENT MARKET SCENARIO
  • 5.2 PORTER'S FIVE FORCES
    • 5.2.1 BARGAINING POWER OF SUPPLIERS
    • 5.2.2 BARGAINING POWER OF CONSUMERS
    • 5.2.3 THREATS OF NEW ENTRANTS
    • 5.2.4 THREAT OF SUBSTITUTE PRODUCT AND SERVICES
    • 5.2.5 COMPETITIVE RIVALRY WITHIN THE INDUSTRY

6. DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES ANALYSIS (DROC)

  • 6.1 MARKET DRIVERS
    • 6.1.1 INCREASING ADOPTION OF STEM CELL TECHNOLOGY
    • 6.1.2 INCREASING PREVALENCE OF CHRONIC DISEASES
    • 6.1.3 EMERGING APPLICATIONS OF GENE THERAPY IN REGENERATIVE MEDICINE
    • 6.1.4 TECHNOLOGICAL ADVANCES IN REGENERATIVE MEDICINE (STEM CELL, TISSUE ENGINEERING, AND NANOTECHNOLOGY)
    • 6.1.5 HIGH INVESTMENT & FUNDING TO SUPPORT DEVELOPMENT OF RM
  • 6.2 MARKET RESTRAINTS
    • 6.2.1 HIGH COST OF TREATMENT AND LESS AWARENESS
    • 6.2.2 REGULATORY AND ETHICAL ISSUES PERTAINING STEM CELL, TISSUES ENGINEERING AND REGENERATIVE MEDICINE
  • 6.3 OPPORTUNITIES
  • 6.4 KEY CHALLENGES

7. MARKET SEGMENTATION

  • 7.1 BY PRODUCT
    • 7.1.1 CELL-BASED PRODUCTS
      • 7.1.1.1 ALLOGENEIC PRODUCTS
      • 7.1.1.2 AUTOLOGOUS PRODUCTS
    • 7.1.2 ACELLULAR PRODUCTS
  • 7.2 BY THERAPY
    • 7.2.1 CELL THERAPY
    • 7.2.2 TISSUE ENGINEERING
    • 7.2.3 IMMUNOTHERAPY
    • 7.2.4 GENE THERAPY
  • 7.3 BY APPLICATION
    • 7.3.1 ORTHOPEDIC & MUSCULOSKELETAL DISORDERS
    • 7.3.2 DERMATOLOGY
    • 7.3.3 CARDIOLOGY
    • 7.3.4 CENTRAL NERVOUS SYSTEM DISEASES
    • 7.3.5 ONCOLOGY
    • 7.3.6 DIABETES
    • 7.3.7 OTHERS
  • 7.4 BY GEOGRAPHY
    • 7.4.1 NORTH AMERICA
      • 7.4.1.1 US
      • 7.4.1.2 CANADA
      • 7.4.1.3 MEXICO
    • 7.4.2 EUROPE
      • 7.4.2.1 FRANCE
      • 7.4.2.2 UK
      • 7.4.2.3 GERMANY
      • 7.4.2.4 ITALY
      • 7.4.2.5 SPAIN
      • 7.4.2.6 REST OF EUROPE
    • 7.4.3 ASIA-PACIFIC
      • 7.4.3.1 INDIA
      • 7.4.3.2 CHINA
      • 7.4.3.3 JAPAN
      • 7.4.3.4 AUSTRALIA
      • 7.4.3.5 SOUTH KOREA
      • 7.4.3.6 REST OF APAC
    • 7.4.4 MIDDLE EAST AND AFRICA
      • 7.4.4.1 GCC
      • 7.4.4.2 SOUTH AFRICA
      • 7.4.4.3 REST OF MIDDLE EAST AND AFRICA
    • 7.4.5 SOUTH AMERICA
      • 7.4.5.1 BRAZIL
      • 7.4.5.2 ARGENTINA
      • 7.4.5.3 REST OF SOUTH AMERICA

8. COMPETITIVE LANDSCAPE

  • 8.1 MERGERS AND ACQUISITIONS
  • 8.2 AGREEMENTS, COLLABORATIONS AND PARTNERSHIPS
  • 8.3 NEW PRODUCT LAUNCHES

9. KEY PLAYERS

  • 9.1 NOVARTIS
  • 9.2 F. HOFFMAN LA-ROCHE LTD.
  • 9.3 MERCK & CO., INC.
  • 9.4 IMMUNOCELLULAR THERAPEUTICS, LTD.
  • 9.5 NOVOCURE
  • 9.6 DEL MAR PHARMACEUTICALS INC.
  • 9.7 MOLECULIN BIOTECH
  • 9.8 OTHERS

10. FUTURE OUTLOOK OF THE MARKET

Back to Top